Dr. Jeffrey W. Sherman joined Horizon in June 2009 as executive vice president, development and regulatory affairs and chief medical officer and throughout his time at Horizon has assumed various responsibilities in addition to chief medical officer.
Before joining Horizon, Dr. Sherman served as senior vice president of research and development and chief medical officer at IDM Pharma, which was acquired by Takeda in 2009. Before IDM Pharma, he served as vice president of clinical science at Takeda Global Research and Development and from September 2000 to June 2007, Dr. Sherman served as chief medical officer and executive vice president at NeoPharm Inc. From October 1992 to August 2000, Dr. Sherman served as director, senior director and executive director of clinical research, and was head of oncology global medical operations at Searle/Pharmacia, or Searle. Dr. Sherman started in industry at Squibb/Bristol-Myers Squibb from April 1988 to September 1992 in clinical pharmacology and clinical research.
Dr. Sherman currently serves as a Drug Information Association (DIA) liaison to the Clinical Trial Transformation Initiative (CTTI), a public-private partnership founded by the U.S. Food and Drug Administration and Duke University to improve the quality and efficiency of clinical trials. From June 2009 to June 2010 he served as president and board member of the DIA. He also serves on the board of advisors of the Center for Information and Study on Clinical Research Participation (CISCRP) a nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media and policy makers about clinical research and the role each party plays in the process.
Dr. Sherman is a member of the Global Genes Medical and Scientific Advisory Board and involved with the National Organization for Rare Disorders (NORD) and the European Organisation for Rare Diseases (EURORDIS). He is also an adjunct assistant professor of medicine at the Northwestern University Feinberg School of Medicine and is a member of a number of professional societies, as well as a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine. Dr. Sherman also serves on the boards of directors of Strongbridge Biopharma and Xeris Pharmaceuticals.
Dr. Sherman received his medical degree from the Rosalind Franklin University/Chicago Medical School. He completed an internal medicine internship, residency and chief medical residency at Northwestern University, as well as fellowship training at the University of California, San Francisco (UCSF). Dr. Sherman was also a research associate at the Howard Hughes Medical Institute at UCSF.
What is Jeffrey W. Sherman's net worth?
The estimated net worth of Jeffrey W. Sherman is at least $628,020.00 as of November 27th, 2023. Dr. Sherman owns 5,400 shares of Horizon Therapeutics Public stock worth more than $628,020 as of December 18th. This net worth evaluation does not reflect any other assets that Dr. Sherman may own. Learn More about Jeffrey W. Sherman's net worth.
How do I contact Jeffrey W. Sherman?
Has Jeffrey W. Sherman been buying or selling shares of Horizon Therapeutics Public?
Jeffrey W. Sherman has not been actively trading shares of Horizon Therapeutics Public during the last ninety days. Most recently, Jeffrey W. Sherman sold 3,368 shares of the business's stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $113.05, for a transaction totalling $380,752.40. Following the completion of the sale, the executive vice president now directly owns 39,539 shares of the company's stock, valued at $4,469,883.95. Learn More on Jeffrey W. Sherman's trading history.
Who are Horizon Therapeutics Public's active insiders?
Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.
